1
|
Xia R, Zhang W, Hang J, Yin Z. Tofacitinib combined with local low-dose ixekizumab injection benefits those with peripheral psoriatic arthritis. J Biomed Res 2023; 38:92-94. [PMID: 37885297 PMCID: PMC10818174 DOI: 10.7555/jbr.37.20220253] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2022] [Revised: 01/11/2023] [Accepted: 01/17/2023] [Indexed: 10/28/2023] Open
Affiliation(s)
- Ruiyuan Xia
- Department of Dermatologythe First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu 210029China
| | - Weixin Zhang
- Department of Ultrasoundthe First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu 210029China
| | - Jing Hang
- Department of Ultrasoundthe First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu 210029China
| | - Zhiqiang Yin
- Department of Dermatologythe First Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu 210029China
| |
Collapse
|
2
|
Bajoria S, Antunez LR, Kumru OS, Klempner M, Wang Y, Cavacini LA, Joshi SB, Volkin DB. Formulation Studies to Develop Low-Cost, Orally-Delivered Secretory IgA Monoclonal Antibodies for Passive Immunization Against Enterotoxigenic Escherichia coli. J Pharm Sci 2023; 112:1832-1844. [PMID: 37040833 DOI: 10.1016/j.xphs.2023.04.005] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/12/2023] [Revised: 04/06/2023] [Accepted: 04/06/2023] [Indexed: 04/13/2023]
Abstract
Enterotoxigenic Escherichia coli (ETEC) is a common cause for diarrheal infections in children in low- and middle-income countries (LMICs). To date, no ETEC vaccine candidates have been approved. Passive immunization with low-cost, oral formulations of secretory IgA (sIgA) against ETEC is an alternative approach to protect high-risk populations in LMICs. Using a model sIgA monoclonal antibody (anti-LT sIgA2-mAb), the stability profiles of different formulations were assessed during storage and in in vitro digestion models (mimicking in vivo oral delivery). First, by employing various physicochemical techniques and a LT-antigen binding assay, three formulations with varying acid-neutralizing capacity (ANC) were evaluated to stabilize sIgA2-mAb during stress studies (freeze-thaw, agitation, elevated temperature) and during exposure to gastric phase digestion. Next, a low-volume, in vitro intestinal digestion model was developed to screen various additives to stabilize sIgA2-mAb in the intestinal phase. Finally, combinations of high ANC buffers and decoy proteins were assessed to collectively protect sIgA2-mAb during in vitro sequential (stomach to intestine) digestion. Based on the results, we demonstrate the feasibility of low-cost, 'single-vial', liquid formulations of sIgA-mAbs delivered orally after infant feeding for passive immunization, and we suggest future work based on a combination of in vitro and in vivo stability considerations.
Collapse
Affiliation(s)
- Sakshi Bajoria
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, KS 66047, USA
| | - Lorena R Antunez
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, KS 66047, USA
| | - Ozan S Kumru
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, KS 66047, USA
| | - Mark Klempner
- MassBiologics of the University of Massachusetts Chan Medical School, Boston, MA 02126, USA
| | - Yang Wang
- MassBiologics of the University of Massachusetts Chan Medical School, Boston, MA 02126, USA
| | - Lisa A Cavacini
- MassBiologics of the University of Massachusetts Chan Medical School, Boston, MA 02126, USA
| | - Sangeeta B Joshi
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, KS 66047, USA
| | - David B Volkin
- Department of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center (VAFC), University of Kansas, Lawrence, KS 66047, USA.
| |
Collapse
|
3
|
Potential Therapeutic Targets for Combination Antibody Therapy against Pseudomonas aeruginosa Infections. Antibiotics (Basel) 2021; 10:antibiotics10121530. [PMID: 34943742 PMCID: PMC8698887 DOI: 10.3390/antibiotics10121530] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Revised: 12/03/2021] [Accepted: 12/09/2021] [Indexed: 12/12/2022] Open
Abstract
Despite advances in antimicrobial therapy and even the advent of some effective vaccines, Pseudomonas aeruginosa (P. aeruginosa) remains a significant cause of infectious disease, primarily due to antibiotic resistance. Although P. aeruginosa is commonly treatable with readily available therapeutics, these therapies are not always efficacious, particularly for certain classes of patients (e.g., cystic fibrosis (CF)) and for drug-resistant strains. Multi-drug resistant P. aeruginosa infections are listed on both the CDC’s and WHO’s list of serious worldwide threats. This increasing emergence of drug resistance and prevalence of P. aeruginosa highlights the need to identify new therapeutic strategies. Combinations of monoclonal antibodies against different targets and epitopes have demonstrated synergistic efficacy with each other as well as in combination with antimicrobial agents typically used to treat these infections. Such a strategy has reduced the ability of infectious agents to develop resistance. This manuscript details the development of potential therapeutic targets for polyclonal antibody therapies to combat the emergence of multidrug-resistant P. aeruginosa infections. In particular, potential drug targets for combinational immunotherapy against P. aeruginosa are identified to combat current and future drug resistance.
Collapse
|
4
|
Fayd'herbe De Maudave A, Leconet W, Toupet K, Constantinides M, Bossis G, de Toledo M, Vialaret J, Hirtz C, Lopez-Noriega A, Jorgensen C, Noël D, Louis-Plence P, Grizot S, Villalba M. Intra-articular delivery of full-length antibodies through the use of an in situ forming depot. J Control Release 2021; 341:578-590. [PMID: 34915070 DOI: 10.1016/j.jconrel.2021.12.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2021] [Revised: 11/29/2021] [Accepted: 12/06/2021] [Indexed: 12/20/2022]
Abstract
Monoclonal antibodies (mAbs) are large size molecules that have demonstrated high therapeutic potential for the treatment of cancer or autoimmune diseases. Despite some excellent results, their intravenous administration results in high plasma concentration. This triggers off-target effects and sometimes poor targeted tissue distribution. To circumvent this issue, we investigated a local controlled-delivery approach using an in situ forming depot technology. Two clinically relevant mAbs, rituximab (RTX) and daratumumab (DARA), were formulated using an injectable technology based on biodegradable PEG-PLA copolymers. The stability and controlled release features of the formulations were investigated. HPLC and mass spectrometry revealed the preservation of the protein structure. In vitro binding of formulated antibodies to their target antigens and to their cellular FcγRIIIa natural killer cell receptor was fully maintained. Furthermore, encapsulated RTX was as efficient as classical intravenous RTX treatment to inhibit the in vivo tumor growth of malignant human B cells in immunodeficient NSG mice. Finally, the intra-articular administration of the formulated mAbs yielded a sustained local release associated with a lower plasma concentration compared to the intra-articular delivery of non-encapsulated mAbs. Our results demonstrate that the utilization of this polymeric technology is a reliable alternative for the local delivery of fully functional clinically relevant mAbs.
Collapse
Affiliation(s)
| | | | | | - Michael Constantinides
- IRMB, Univ Montpellier, INSERM, Montpellier, France; IRMB, CHU Montpellier, Montpellier, France
| | | | | | | | | | | | - Christian Jorgensen
- IRMB, Univ Montpellier, INSERM, Montpellier, France; IRMB, CHU Montpellier, Montpellier, France
| | - Daniele Noël
- IRMB, Univ Montpellier, INSERM, Montpellier, France; IRMB, CHU Montpellier, Montpellier, France
| | | | | | - Martin Villalba
- IRMB, Univ Montpellier, INSERM, Montpellier, France; IRMB, CHU Montpellier, Montpellier, France; IRMB, Univ Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France; Institut Sainte-Catherine, Avignon, France.
| |
Collapse
|
5
|
Parray HA, Shukla S, Perween R, Khatri R, Shrivastava T, Singh V, Murugavelu P, Ahmed S, Samal S, Sharma C, Sinha S, Luthra K, Kumar R. Inhalation monoclonal antibody therapy: a new way to treat and manage respiratory infections. Appl Microbiol Biotechnol 2021; 105:6315-6332. [PMID: 34423407 PMCID: PMC8380517 DOI: 10.1007/s00253-021-11488-4] [Citation(s) in RCA: 42] [Impact Index Per Article: 14.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 07/14/2021] [Accepted: 07/30/2021] [Indexed: 12/23/2022]
Abstract
The route of administration of a therapeutic agent has a substantial impact on its success. Therapeutic antibodies are usually administered systemically, either directly by intravenous route, or indirectly by intramuscular or subcutaneous injection. However, treatment of diseases contained within a specific tissue necessitates a better alternate route of administration for targeting localised infections. Inhalation is a promising non-invasive strategy for antibody delivery to treat respiratory maladies because it provides higher concentrations of antibody in the respiratory airways overcoming the constraints of entry through systemic circulation and uncertainity in the amount reaching the target tissue. The nasal drug delivery route is one of the extensively researched modes of administration, and nasal sprays for molecular drugs are deemed successful and are presently commercially marketed. This review highlights the current state and future prospects of inhaled therapies, with an emphasis on the use of monoclonal antibodies for the treatment of respiratory infections, as well as an overview of their importance, practical challenges, and clinical trial outcomes.Key points• Immunologic strategies for preventing mucosal transmission of respiratory pathogens.• Mucosal-mediated immunoprophylaxis could play a major role in COVID-19 prevention.• Applications of monoclonal antibodies in passive immunisation.
Collapse
Affiliation(s)
- Hilal Ahmad Parray
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Shivangi Shukla
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Reshma Perween
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Ritika Khatri
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Tripti Shrivastava
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Vanshika Singh
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Praveenkumar Murugavelu
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Shubbir Ahmed
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Sweety Samal
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Chandresh Sharma
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India
| | - Subrata Sinha
- Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Kalpana Luthra
- Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India
| | - Rajesh Kumar
- Translational Health Science & Technology Institute, NCR Biotech Science Cluster, 3rd Milestone, Faridabad - Gurgaon Expressway, PO Box # 04, Faridabad, Haryana, 121001, India.
| |
Collapse
|
6
|
Tran PHL, Tran TTD. Current Film Coating Designs for Colon-Targeted Oral Delivery. Curr Med Chem 2021; 28:1957-1969. [PMID: 32496984 DOI: 10.2174/0929867327666200604170048] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/07/2020] [Revised: 05/02/2020] [Accepted: 05/03/2020] [Indexed: 11/22/2022]
Abstract
Colon-targeted oral delivery has recently attracted a substantial number of studies on both systemic and local treatments. Among approaches for colonic delivery, film coatings have been demonstrated as effective elements of the drug delivery systems because they can integrate multiple release strategies, such as pH-controlled release, time-controlled release and enzyme-triggered release. Moreover, coating layer modulations, natural film materials and nanoparticle coatings have been vigorously investigated with promising applications. This review aims to describe the primary approaches for improving drug delivery to the colon in the last decade. The outstanding importance of current developments in film coatings will advance dosage form designs and lead to the development of efficient colon-targeted oral delivery systems.
Collapse
Affiliation(s)
| | - Thao T D Tran
- Department for Management of Science and Technology Development, Ton Duc Thang University, Ho Chi Minh City, Vietnam
| |
Collapse
|
7
|
Vass P, Démuth B, Hirsch E, Nagy B, Andersen SK, Vigh T, Verreck G, Csontos I, Nagy ZK, Marosi G. Drying technology strategies for colon-targeted oral delivery of biopharmaceuticals. J Control Release 2019; 296:162-178. [PMID: 30677436 DOI: 10.1016/j.jconrel.2019.01.023] [Citation(s) in RCA: 44] [Impact Index Per Article: 8.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2018] [Revised: 01/16/2019] [Accepted: 01/17/2019] [Indexed: 12/12/2022]
Abstract
In chronic intestinal diseases like inflammatory bowel disease, parenteral administration of biopharmaceuticals is associated with numerous disadvantages including immune reactions, infections, low patient compliance, and toxicity caused by high systemic bioavailability. One alternative that can potentially overcome these limitations is oral administration of biopharmaceuticals, where the local delivery will reduce the systemic exposure and furthermore the manufacturing costs will be lower. However, the development of oral dosage forms that deliver the biologically active form to the intestines is one of the greatest challenges for pharmaceutical technologists due to the sensitive nature of biopharmaceuticals. The present article discusses the various drug delivery technologies used to produce orally administered solid dosage forms of biopharmaceuticals with an emphasis on colon-targeted delivery. Solid oral dosage compositions containing different types of colon-targeting biopharmaceuticals are compiled followed by a review of currently applied and emerging drying technologies for biopharmaceuticals. The different drying technologies are compared in terms of their advantages, limitations, costs and their effect on product stability.
Collapse
Affiliation(s)
- Panna Vass
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| | - Balázs Démuth
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| | - Edit Hirsch
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| | - Brigitta Nagy
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| | - Sune K Andersen
- Oral Solids Development, Janssen R&D, B-2340 Beerse, Turnhoutseweg 30, Belgium.
| | - Tamás Vigh
- Oral Solids Development, Janssen R&D, B-2340 Beerse, Turnhoutseweg 30, Belgium
| | - Geert Verreck
- Oral Solids Development, Janssen R&D, B-2340 Beerse, Turnhoutseweg 30, Belgium
| | - István Csontos
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| | - Zsombor K Nagy
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary.
| | - György Marosi
- Department of Organic Chemistry and Technology, Budapest University of Technology and Economics (BME), H-1111 Budapest, Műegyetem rakpart 3, Hungary
| |
Collapse
|
8
|
Förster B, Chung PK, Crobach MJT, Kuijper EJ. Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection. Front Microbiol 2018; 9:1382. [PMID: 29988597 PMCID: PMC6027166 DOI: 10.3389/fmicb.2018.01382] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 06/06/2018] [Indexed: 12/17/2022] Open
Abstract
Clostridium difficile causes antibiotic- and healthcare-associated diarrhea, which is characterized by a high mortality rate (5–15%) and high recurrence rate of 20% or more. Therapeutic alternatives to antibiotics are urgently needed to improve the overall cure rate. Among these, therapeutic antibodies have shown promising results in clinical studies. Herein, the authors review current monoclonal and polyclonal anti- C. difficile antibodies that have entered the clinical development stage, either for systemic administration or by the oral route. The antibodies can be applied as monotherapy or in combination with standard-of-care to treat an infection with C. difficile or to protect from a recurrence. Bezlotoxumab is the first antibody for secondary prevention of recurrence of C. difficile infection approved by the regulatory agencies in US and Europe. The human monoclonal antibody is administered systemically to patients receiving oral standard-of–care antibiotics. Other antibodies are currently in the clinical pipeline, and some are intended for oral use. They show a good safety profile, high efficacy and low production costs, and can be considered promising therapies of the future. The most promising orally administered drug candidate is a bovine antibody from hyperimmune colostral milk, which is in an advanced clinical development stage. Which antibody will enter the market is dependent on its bioavailability at the site of infection as well as its activity against C. difficile toxins, protection against colonization and possible action on spore formation. The antibody must demonstrate a clear benefit in comparison with other available treatment options to be considered for use by clinicians.
Collapse
Affiliation(s)
- Beatrix Förster
- Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, Netherlands.,Bijvoet Center for Biomolecular Research, Utrecht University, Utrecht, Netherlands
| | - Pui Khi Chung
- Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
| | - Monique J T Crobach
- Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
| | - Ed J Kuijper
- Department of Medical Microbiology, Centre for Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands
| |
Collapse
|
9
|
DeRosa JR, Moyer BS, Lumen E, Wolfe AJ, Sleeper MB, Bianchi AH, Crawford A, McGuigan C, Wortel D, Fisher C, Moody KJ, Blanden AR. RPtag as an Orally Bioavailable, Hyperstable Epitope Tag and Generalizable Protein Binding Scaffold. Biochemistry 2018; 57:3036-3049. [PMID: 29722979 DOI: 10.1021/acs.biochem.8b00170] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
Antibodies are the most prolific biologics in research and clinical environments because of their ability to bind targets with high affinity and specificity. However, antibodies also carry liabilities. A significant portion of the life-science reproducibility crisis is driven by inconsistent performance of research-grade antibodies, and clinical antibodies are often unstable and require costly cold-chain management to reach their destinations in active form. In biotechnology, antibodies are also limited by difficulty integrating them in many recombinant systems due to their size and structural complexity. A switch to small, stable, sequence-verified binding scaffolds may overcome these barriers. Here we present such a scaffold, RPtag, based on a ribose-binding protein (RBP) from extremophile Caldanaerobacter subterraneus. RPtag binds an optimized peptide with pM affinity, is stable to extreme temperature, pH, and protease treatment, readily refolds after denaturation, is effective in common laboratory applications, was rationally engineered to bind bioactive PDGF-β, and was formulated as a gut-stable orally bioavailable preparation.
Collapse
Affiliation(s)
- Jennifer R DeRosa
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Brandon S Moyer
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Ellie Lumen
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Aaron J Wolfe
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Meegan B Sleeper
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Anthony H Bianchi
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Ashleigh Crawford
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Connor McGuigan
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Danique Wortel
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Cheyanne Fisher
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Kelsey J Moody
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| | - Adam R Blanden
- Ichor Therapeutics, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States.,RecombiPure, Inc. , 2521 US-11 , Lafayette , New York 13084 , United States
| |
Collapse
|
10
|
Ghiciuc CM, Strat AL, Ochiuz L, Lupusoru CE, Ignat M, Vasile A, Grigorovici A, Stoleriu I, Solcan C. Inhibition of bcl-2 and cox-2 Protein Expression after Local Application of a New Carmustine-Loaded Clinoptilolite-Based Delivery System in a Chemically Induced Skin Cancer Model in Mice. Molecules 2017; 22:molecules22112014. [PMID: 29156646 PMCID: PMC6150160 DOI: 10.3390/molecules22112014] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/27/2017] [Accepted: 11/06/2017] [Indexed: 02/07/2023] Open
Abstract
Our research has focused on in vitro and in vivo evaluations of a new Carmustine (BCNU)-loaded clinoptilolite-based delivery system. Two clinoptilolite ionic forms-hydrogen form (HCLI) and sodium form (NaCLI)-were prepared, allowing a loading degree of about 5-6 mg BCNU/g of zeolite matrix due to the dual porous feature of clinoptilolite. Clinoptilolite-based delivery systems released 35.23% of the load in 12 h for the BCNU@HCLI system and only 10.82% for the BCNU@NaCLI system. The BCNU@HCLI system was chosen to develop gel and cream semisolid dosage forms. The cream (C_BCNU@HCLI) released 29.6% of the loaded BCNU after 12 h in the Nylon synthetic membrane test and 31.6% in the collagen membrane test, higher by comparison to the gel. The new cream was evaluated in vivo in a chemically induced model of skin cancer in mice. Quantitative immunohistochemistry analysis showed stronger inhibition of B-cell lymphoma-2 (bcl-2) and cyclooxygenase 2 (cox-2) protein expression, known markers for cancer survival and aggressiveness, after the treatment with C_BCNU@HCLI by comparison to all the control treatment types, including an off-label magistral formula commercially available Carmustine cream as reference, bringing evidence that a clinoptilolite-based delivery systems could be used as a cancer drug carriers and controlled release systems (skin-targeted topical delivery systems).
Collapse
Affiliation(s)
- Cristina Mihaela Ghiciuc
- Department of Pharmacology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania.
| | - Aurel Lulu Strat
- Department of Pharmacology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania.
- Laboratory of Microbiology, Hospital of Infectious Diseases "Saint Parascheva", 2, Octav Botez Street, 700116 Iasi, Romania.
| | - Lacramioara Ochiuz
- Department of Pharmaceutical Technology, Faculty of Pharmacy, "Grigore T. Popa" University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania.
| | - Catalina Elena Lupusoru
- Department of Pharmacology, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania.
| | - Maria Ignat
- Faculty of Chemistry, "Al. I. Cuza" University, 11, Blvd. Carol the 1st, 700560 Iasi, Romania.
| | - Aurelia Vasile
- Faculty of Chemistry, "Al. I. Cuza" University, 11, Blvd. Carol the 1st, 700560 Iasi, Romania.
| | - Alexandru Grigorovici
- Department of Surgery, Faculty of Medicine, "Grigore T. Popa" University of Medicine and Pharmacy, 16, University Street, 700115 Iasi, Romania.
| | - Iulian Stoleriu
- Faculty of Mathematics, "Al. I. Cuza" University, 11, Blvd. Carol the 1st, 700506 Iasi, Romania.
| | - Carmen Solcan
- Department of Molecular Biology, Histology and Embriology, Faculty of Veterinary Medicine, University of Agricultural Science and Veterinary Medicine "Ion Ionescu de la Brad", 8, Mihail Sadoveanu Alley, 700489 Iasi, Romania.
| |
Collapse
|
11
|
Adegbola SO, Sahnan K, Tozer PJ, Phillips RK, Faiz OD, Warusavitarne J, Hart A. Review of local injection of anti-TNF for perianal fistulising Crohn's disease. Int J Colorectal Dis 2017; 32:1539-1544. [PMID: 28900730 PMCID: PMC5635080 DOI: 10.1007/s00384-017-2899-0] [Citation(s) in RCA: 22] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 08/30/2017] [Indexed: 02/04/2023]
Abstract
BACKGROUND Perianal fistulising Crohn's disease (PFCD) affects a third of Crohn's disease patients and represents a disabling phenotype with poor outcome. The anti-tumour necrosis factor alpha (TNF) therapies have been shown to maintain clinical remission in a third of patients after 1 year of treatment. Maintenance therapy with systematic administration schedules confers greatest benefit, but exposes patients to risks/side effects of continued systemic use and led to consideration of local drug delivery (first described in 2000). In this review, we analyse all published articles on local anti-TNF therapy in the treatment of PFCD. METHODS The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were used to systematically search Medline and Embase using the medical subject headings 'fistula', 'anus', 'Crohn disease', 'infliximab' and 'adalimumab'. This was combined with free text searches, e.g. 'local injection' and 'Crohn's perianal disease'. Studies/abstracts describing local injection treatment with anti-TNF were included in this review. RESULTS Six pilot studies including a total of 92 patients were included in this review. Outcomes reported were mostly clinical and included 'complete/partial response' to therapy and short-term results varied between 40 and 100%. There were no significant adverse events and the local injections were well tolerated. CONCLUSIONS There is paucity of data assessing this treatment modality. Local anti-TNF therapy appears safe, but outcome reporting is heterogeneous, subjective and long-term data are unavailable. Our review suggests a potential role may be in those in whom systemic treatment is contraindicated and calls for standardised reporting of outcomes in this field to enable better data interpretation.
Collapse
Affiliation(s)
- Samuel O Adegbola
- Surgical Epidemiology, Trials and Outcome Centre (SETOC), St Mark's Hospital and Academic Institute, Harrow, Middlesex, HA1 3UJ, UK.
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK.
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK.
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK.
| | - Kapil Sahnan
- Surgical Epidemiology, Trials and Outcome Centre (SETOC), St Mark's Hospital and Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| | - Philip J Tozer
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| | - Robin Ks Phillips
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| | - Omar D Faiz
- Surgical Epidemiology, Trials and Outcome Centre (SETOC), St Mark's Hospital and Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| | - Janindra Warusavitarne
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| | - Ailsa Hart
- Department of Surgery, Imperial College, St Mary's Hospital, Praed Street, London, W2 1NY, UK
- St Mark's Hospital, Watford Road, Harrow, HA1 3UJ, UK
- Fistula Research Unit, St Mark's Academic Institute, Harrow, Middlesex, HA1 3UJ, UK
| |
Collapse
|
12
|
Abstract
Clostridium difficile continues to be one of the most prevalent hospital-acquired bacterial infections in the developed world, despite the recent introduction of a novel and effective antibiotic agent (fidaxomicin). Alternative approaches under investigation to combat the anaerobic Gram-positive bacteria include fecal transplantation therapy, vaccines, and antibody-based immunotherapies. In this review, we catalog the recent advances in antibody-based approaches under development and in the clinic for the treatment of C. difficile infection. By and large, inhibitory antibodies that recognize the primary C. difficile virulence factors, toxin A and toxin B, are the most popular passive immunotherapies under investigation. We provide a detailed summary of the toxin epitopes recognized by various antitoxin antibodies and discuss general trends on toxin inhibition efficacy. In addition, antibodies to other C. difficile targets, such as surface-layer proteins, binary toxin, motility factors, and adherence and colonization factors, are introduced in this review.
Collapse
Affiliation(s)
- Greg Hussack
- Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa
| | - Jamshid Tanha
- Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa; School of Environmental Sciences, University of Guelph, Guelph; Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada
| |
Collapse
|
13
|
Oral delivery of macromolecular drugs: Where we are after almost 100years of attempts. Adv Drug Deliv Rev 2016; 101:108-121. [PMID: 26826437 DOI: 10.1016/j.addr.2016.01.010] [Citation(s) in RCA: 203] [Impact Index Per Article: 25.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2015] [Revised: 01/11/2016] [Accepted: 01/18/2016] [Indexed: 02/08/2023]
Abstract
Since the first attempt to administer insulin orally in humans more than 90years ago, the oral delivery of macromolecular drugs (>1000g/mol) has been rather disappointing. Although several clinical pilot studies have demonstrated that the oral absorption of macromolecules is possible, the bioavailability remains generally low and variable. This article reviews the formulations and biopharmaceutical aspects of orally administered biomacromolecules on the market and in clinical development for local and systemic delivery. The most successful approaches for systemic delivery often involve a combination of enteric coating, protease inhibitors and permeation enhancers in relatively high amounts. However, some of these excipients have induced local or systemic adverse reactions in preclinical and clinical studies, and long-term studies are often missing. Therefore, strategies aimed at increasing the oral absorption of macromolecular drugs should carefully take into account the benefit-risk ratio. In the absence of specific uptake pathways, small and potent peptides that are resistant to degradation and that present a large therapeutic window certainly represent the best candidates for systemic absorption. While we acknowledge the need for systemically delivering biomacromolecules, it is our opinion that the oral delivery to local gastrointestinal targets is currently more promising because of their accessibility and the lacking requirement for intestinal permeability enhancement.
Collapse
|
14
|
Jones RG, Martino A. Linear models of ovine IgG1 and IgG2 subclasses and predicted pepsin cleavage sites. J Pharm Biomed Anal 2016; 117:150-4. [DOI: 10.1016/j.jpba.2015.08.035] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/06/2015] [Revised: 08/25/2015] [Accepted: 08/27/2015] [Indexed: 10/23/2022]
|
15
|
IgG-loaded hyaluronan-based dissolving microneedles for intradermal protein delivery. J Control Release 2015; 218:53-62. [DOI: 10.1016/j.jconrel.2015.10.002] [Citation(s) in RCA: 66] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2015] [Revised: 09/29/2015] [Accepted: 10/01/2015] [Indexed: 01/06/2023]
|